Assessment of effectiveness and impact of universal prophylaxis with nirsevimab for prevention of hospitalizations due to respiratory syncytial virus in infants. The NIRSE-GAL study protocol
Nirsevimab has been recently licensed for universal RSV prophylaxis in infants. NIRSE-GAL is a three-year population-based study initiated in Galicia in September 2023.
Targeted metagenomics reveals association between severity and pathogen co-detection in infants with respiratory syncytial virus
Respiratory syncytial virus (RSV) is the leading cause of hospitalisation for respiratory infection in young children.
|
ESWI Respiratory Virus Summit 2024
ESWI Summit 2024: Conclusions
Conclusions by Peter Openshaw, Co-Chair of the the ESWI Respiratory Virus Summit 2024
|
ESWI Respiratory Virus Summit 2024
ESWI Summit 2024: Science Policy Interface debate
How to ensure/prepare for access to immunisation programmes
|
ESWI Respiratory Virus Summit 2024
ESWI Summit 2024: Rapporteur from the RSVVW’ 2024 meeting in Mumbai
By Ab Osterhaus, Host of the ESWI Respiratory Virus Summit 2024
|
ESWI Respiratory Virus Summit 2024
ESWI Summit 2024: What's in the pipeline?
Live attenuated vaccines; NIRSE-GAL: Evaluation of the effectiveness and impact of Nirsevimab in Galicia; and Therapeutics
|
ESWI Respiratory Virus Summit 2024
ESWI Summit 2024: Early Career Scientists
ESWI Summit 2024: Early Career Scientists They each delivered a presentation introducing themselves and their ongoing work on RSV, bringing innovative ideas and making clear calls for action.
|
ESWI Respiratory Virus Summit 2024
ESWI Summit 2024: Diagnostics and Point of Care Testing
Keynote Lecture by Dexter Wiseman, Imperial College London
|
ESWI Respiratory Virus Summit 2024
ESWI Summit 2024: Burden of disease in older adults
Keynote Lecture by Stefan Gravenstein, Brown University
|
ESWI Respiratory Virus Summit 2024
ESWI Summit 2024: Burden of disease in infants
Keynote Lecture by Simon Drysdale, St George's University Hospitals NHS Foundation Trust
In Utero Exposure to Maternal COVID-19 Vaccination and Offspring Neurodevelopment at 12 and 18 Months
Uptake of COVID-19 vaccines among pregnant individuals was hampered by safety concerns around potential risks to unborn children.
Scientific Papers
Article
News
Early estimates of nirsevimab immunoprophylaxis effectiveness against hospital admission for respiratory syncytial virus lower respiratory tract infections in infants, Spain, October 2023 to January 2024
Respiratory syncytial virus (RSV) is the leading cause of acute lower respiratory tract infections (LRTI) in children.
